Review article: The need for more efficient and patient-oriented drug development pathways in NASH-setting the scene for platform trials.
Juan Manuel PericàsNicholas A Di ProsperoQuentin Mark AnsteePeter MesenbrinckMette S KjaerJesus Manuel Rivera EstebanFranz KoenigElena SenaRaluca PaisRamiro ManzanoJoan GenescàFrank TackeVlad Ratziunull nullPublished in: Alimentary pharmacology & therapeutics (2023)
PT represent a promising avenue in NASH but there are a number of conundrums that need addressing. It is likely that before a global NASH PT becomes a reality, 'proof-of-platform' at a smaller scale needs to be provided.
Keyphrases